Crossman A - Search Results

1

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Fox SH, et al. Among authors: crossman a. Mov Disord. 2002 Nov;17(6):1180-7. doi: 10.1002/mds.10289. Mov Disord. 2002. PMID: 12465055

2

Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.

Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J. Fox S, et al. Among authors: crossman a. Mov Disord. 2004 May;19(5):554-60. doi: 10.1002/mds.10693. Mov Disord. 2004. PMID: 15133820 Clinical Trial.

3

Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.

Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Fox SH, et al. Among authors: crossman ar. Mov Disord. 2002 Jan;17(1):145-9. doi: 10.1002/mds.1280. Mov Disord. 2002. PMID: 11835452 Clinical Trial.

4

Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.

Segovia G, Mora F, Crossman AR, Brotchie JM. Segovia G, et al. Mov Disord. 2003 Feb;18(2):138-49. doi: 10.1002/mds.10312. Mov Disord. 2003. PMID: 12539206

5

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. Savola JM, et al. Mov Disord. 2003 Aug;18(8):872-83. doi: 10.1002/mds.10464. Mov Disord. 2003. PMID: 12889076

6

Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.

Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Henry B, et al. Exp Neurol. 2003 Oct;183(2):458-68. doi: 10.1016/s0014-4886(03)00064-5. Exp Neurol. 2003. PMID: 14552886

7

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.

Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Hill MP, et al. Among authors: crossman ar. Mov Disord. 2003 Nov;18(11):1301-5. doi: 10.1002/mds.10542. Mov Disord. 2003. PMID: 14639671

8

Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.

Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Hill MP, et al. Among authors: crossman ar. J Pharmacol Exp Ther. 2004 Jul;310(1):386-94. doi: 10.1124/jpet.104.066191. Epub 2004 Mar 5. J Pharmacol Exp Ther. 2004. PMID: 15004218

9

Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets.

Hill MP, Brotchie JM, Crossman AR, Bezard E, Michel A, Grimée R, Klitgaard H. Hill MP, et al. Among authors: crossman ar. Clin Neuropharmacol. 2004 Jul-Aug;27(4):171-7. doi: 10.1097/01.wnf.0000135478.70905.3d. Clin Neuropharmacol. 2004. PMID: 15319703

10

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.

Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ. Hill MP, et al. Mov Disord. 2006 Dec;21(12):2090-5. doi: 10.1002/mds.21106. Mov Disord. 2006. PMID: 16991143

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

246 results

Search Page

Filters